221 related articles for article (PubMed ID: 34626090)
41. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization.
Kovacs G; Maier R; Aberer E; Brodmann M; Scheidl S; Hesse C; Troester N; Salmhofer W; Stauber R; Fuerst FC; Thonhofer R; Ofner-Kopeinig P; Gruenig E; Olschewski H
Chest; 2010 Aug; 138(2):270-8. PubMed ID: 20418368
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension.
Abston E; Moll M; Hon S; Govender P; Berman J; Farber H
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):184-191. PubMed ID: 33093782
[TBL] [Abstract][Full Text] [Related]
43. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
[TBL] [Abstract][Full Text] [Related]
44. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
Yasuoka H; Shirai Y; Tamura Y; Takeuchi T; Kuwana M
Circ J; 2018 Jan; 82(2):546-554. PubMed ID: 28904255
[TBL] [Abstract][Full Text] [Related]
45. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
[TBL] [Abstract][Full Text] [Related]
46. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
[TBL] [Abstract][Full Text] [Related]
47. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
[TBL] [Abstract][Full Text] [Related]
48. Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension.
Hajian B; De Backer J; Vos W; Van Holsbeke C; Ferreira F; Quinn DA; Hufkens A; Claes R; De Backer W
Int J Chron Obstruct Pulmon Dis; 2016; 11():1533-41. PubMed ID: 27462149
[TBL] [Abstract][Full Text] [Related]
49. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
51. Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients.
Giordano N; Montella A; Corallo C; Ruocco G; Chirico C; Palazzuoli A; Nuti R; Pecetti G
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S182-9. PubMed ID: 26339897
[TBL] [Abstract][Full Text] [Related]
52. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J
J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592
[TBL] [Abstract][Full Text] [Related]
53. [Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
Volkov AV; Iudkina NN; Nikolaeva EV; Kurmukov IA; Glukhova SI; Nasonov EL
Ter Arkh; 2014; 86(5):32-9. PubMed ID: 25026800
[TBL] [Abstract][Full Text] [Related]
54. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
55. Comparative Effect of Levosimendan and Milrinone in Cardiac Surgery Patients With Pulmonary Hypertension and Left Ventricular Dysfunction.
Mishra A; Kumar B; Dutta V; Arya VK; Mishra AK
J Cardiothorac Vasc Anesth; 2016 Jun; 30(3):639-46. PubMed ID: 27321790
[TBL] [Abstract][Full Text] [Related]
56. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Cavusoglu Y; Beyaztas A; Birdane A; Ata N
J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):503-7. PubMed ID: 19346968
[TBL] [Abstract][Full Text] [Related]
57. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
58. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.
Sanchez O; Sitbon O; Jaïs X; Simonneau G; Humbert M
Chest; 2006 Jul; 130(1):182-9. PubMed ID: 16840400
[TBL] [Abstract][Full Text] [Related]
59. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
Mittoo S; Jacob T; Craig A; Bshouty Z
Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
[TBL] [Abstract][Full Text] [Related]
60. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
